GB201111382D0 - Use of prodrugs to avoid GI medicated adverse events - Google Patents
Use of prodrugs to avoid GI medicated adverse eventsInfo
- Publication number
- GB201111382D0 GB201111382D0 GBGB1111382.6A GB201111382A GB201111382D0 GB 201111382 D0 GB201111382 D0 GB 201111382D0 GB 201111382 A GB201111382 A GB 201111382A GB 201111382 D0 GB201111382 D0 GB 201111382D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- medicated
- prodrugs
- avoid
- adverse events
- adverse
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1111382.6A GB201111382D0 (en) | 2011-07-04 | 2011-07-04 | Use of prodrugs to avoid GI medicated adverse events |
US13/253,677 US20120202756A1 (en) | 2009-04-02 | 2011-10-05 | Use of prodrugs to avoid gi mediated adverse events |
PCT/GB2011/051911 WO2012046062A1 (en) | 2010-10-05 | 2011-10-05 | Use of prodrugs to avoid gi mediated adverse events |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1111382.6A GB201111382D0 (en) | 2011-07-04 | 2011-07-04 | Use of prodrugs to avoid GI medicated adverse events |
Publications (1)
Publication Number | Publication Date |
---|---|
GB201111382D0 true GB201111382D0 (en) | 2011-08-17 |
Family
ID=44512054
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB1111382.6A Ceased GB201111382D0 (en) | 2009-04-02 | 2011-07-04 | Use of prodrugs to avoid GI medicated adverse events |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB201111382D0 (en) |
-
2011
- 2011-07-04 GB GBGB1111382.6A patent/GB201111382D0/en not_active Ceased
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL255045A0 (en) | Crystal of flumioxazin | |
EP2742051A4 (en) | Amorphous form of dolutegravir | |
EP2709694A4 (en) | Single-use injector of low cost | |
EP2791364A4 (en) | Methods of responding to a biothreat | |
EP2712362A4 (en) | Manufacture of lacto-n-tetraose | |
GB201104096D0 (en) | Production of graphene | |
EP2521545A4 (en) | Prodrugs of heteraromatic compounds | |
EP2706992A4 (en) | Anxiolytic effect of pterostilbene | |
SG11201402112RA (en) | Use of humanized mice to determine toxicity | |
CO6791617A2 (en) | Combinations of active compounds | |
HK1192323A1 (en) | Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles glu- | |
HK1203355A1 (en) | Uses of 4-desferrithiocin analogs 4- | |
PL2753330T3 (en) | Therapeutic uses of ectoin | |
EP2756418A4 (en) | Distributing events to large numbers of devices | |
GB201104001D0 (en) | Improvements to goggles | |
IL259184B (en) | Crystal of flumioxazin | |
EP2830614A4 (en) | Cyclic prodrugs of duocarmycin analogs | |
CO6821942A2 (en) | Combinations of active compounds | |
ZA201307229B (en) | Prodrugs of d-isoglutamyl-[d/l]- tryprophan | |
ZA201307230B (en) | Prodrugs of d-gamma-glutamyl-d-tryptophan and d-gamma-glutamyl-l-tryptophan | |
IL230977A (en) | Crystalline form of rilapladib | |
EP2726505A4 (en) | Therapeutic targeting of ficolin-3 | |
GB201111382D0 (en) | Use of prodrugs to avoid GI medicated adverse events | |
GB201111378D0 (en) | Use of prodrugs to avoid GI medicated adverse events | |
GB201016752D0 (en) | Use of prodrugs to avoid gi mediated adverse events |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |